If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Area of Expertise

My research is focused on enhancing therapeutic efficacy in cancer. I have collaborated with Dr. Andras Lacko on the development of a lipoprotein-based targeted drug delivery vehicle for cancer chemotherapeutic agents. Also, I collaborate with Dr. Riyaz Basha in investigating the strategies to induce therapeutic efficacy of the chemotherapeutic agents used in standard care. We are investigating the effect of combination therapy of standard chemotherapeutic agents with clotum and Mithramicin for Ewing sarcoma, medulloblastoma, and neuroblastoma cell lines.

Education/Academic qualification

PhD in Chemistry, University of Kerala

MS in Applied Chemistry, Cochin University of Science and Technology

BS in Chemistry, University of Kerala

Fingerprint Dive into the research topics where Maya Nair is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Phosphatidylcholine-Sterol O-Acyltransferase Medicine & Life Sciences
HDL Lipoproteins Medicine & Life Sciences
Nanoparticles Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
valrubicin Medicine & Life Sciences
Lipoproteins Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Research Output 1997 2019

  • 585 Citations
  • 10 h-Index
  • 18 Article
  • 1 Review article
1 Citation (Scopus)
Open Access
Translational Medical Research
Organized Financing
Self Efficacy
33 Citations (Scopus)

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

Sabnis, N., Nair, M. P., Israel, M., McConathy, W. J. & Lacko, A. G., 5 Dec 2012, In : International Journal of Nanomedicine. 7, p. 975-983 9 p.

Research output: Contribution to journalArticleResearchpeer-review

128 Citations (Scopus)

Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles

Shahzad, M. M. K., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., Mora, E. M., Lee, J. W., Stone, R. L., Pecot, C. V., Thanapprapasr, D., Roh, J. W., Gaur, P., Nair, M. P., Park, Y. Y., Sabnis, N., Deavers, M. T., Lee, J. S., Ellis, L. M., Lopez-Berestei, G. & 4 others, McConathy, W. J., Prokai, L., Lacko, A. G. & Sood, A. K., 1 Jan 2011, In : Neoplasia. 13, 4, p. 309-319 11 p.

Research output: Contribution to journalArticleResearchpeer-review

HDL Lipoproteins
Small Interfering RNA
Scavenger Receptors
10 Citations (Scopus)

Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)

McConathy, W. J., Paranjape, S., Mooberry, L., Buttreddy, S., Nair, M. P. & Lacko, A. G., 1 Apr 2011, In : Drug Delivery and Translational Research. 1, 2, p. 113-120 8 p.

Research output: Contribution to journalArticleResearchpeer-review

HDL Lipoproteins
Pharmaceutical Preparations
lauric acid
81 Citations (Scopus)

Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier

Mooberry, L. K., Nair, M. P., Paranjape, S., McConathy, W. J. & Lacko, A. G., 1 Jan 2010, In : Journal of Drug Targeting. 18, 1, p. 53-58 6 p.

Research output: Contribution to journalArticleResearchpeer-review

HDL Lipoproteins
Scavenger Receptors
Pharmaceutical Preparations